Chemical structure of molecule compound 1 Novartis RET inhibitor

oral RET kinase inhibitor

effective in tumor xenograft model

from scaffold hopping & optimization

ACS Medicinal Chemistry Letters

Novartis Genomics Institute

14.  The Novartis RET inhibitor, compound 1, demonstrated robust oral in vivo efficacy in RET-driven tumor xenografts at low doses (10 mpk QD). RET inhibitors (selpercatinib and pralsetinib) have recently been approved…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.